Bipartisan group pushes CMS to expand coverage for Alzheimer’s treatments
By
Kimberly Bonvissuto
Feb 21, 2023
Access to federally approved monoclonal antibody and other disease-modifying therapies for Alzheimer’s disease will be “extremely limited” unless the Centers for Medicare & Medicaid Services reconsiders...
Alzheimer’s research, treatments prioritized in 2 bills taken up by Congress
By
Kimberly Bonvissuto
Feb 06, 2023
Two bipartisan bills prioritizing Alzheimer’s research and supporting scientists in the development of treatments for the disease were reintroduced in Congress last week.
More news for Tuesday, Dec. 13
By
Kimberly Bonvissuto
Dec 13, 2022
Lawmakers call for improved access to brain scans in diagnosing Alzheimer’s disease … Federal judge strikes down Montana vaccine choice law in healthcare settings … Juniper Communities receives SageCare...
Alzheimer’s experts throw support behind experimental drug despite adverse events, deaths
By
Kimberly Bonvissuto
Dec 01, 2022
Alzheimer’s disease experts are throwing their support behind the drug lecanemab, despite reports of two deaths tied to the experimental monoclonal antibody medication.
Progress made in Alzheimer’s research and lifestyle interventions, NIH says
By
Kimberly Bonvissuto
Nov 30, 2022
The burden of Alzheimer’s disease and related dementias is significant, according to the National Institutes of Health. But scientists have made progress in drug development, lifestyle interventions,...
Dementia: Detection possible 9 years before diagnosis and could lead to earlier interventions, researchers...
By
Kimberly Bonvissuto
Oct 18, 2022
Detecting signs of dementia up to nine years before diagnosis is possible and could lead to earlier interventions to reduce development of the disease and help recruit people to participate in clinical...
More news for Friday, Oct. 14
By
Kimberly Bonvissuto
Oct 14, 2022
First LGBTQ+ Medicare Advantage plan for older adults launches … $1 million grant aims to reduce fall risk in older adults … New model predicts five-year Alzheimer’s risk … Dietary habits at midlife...
Promising Alzheimer’s drug results hailed as ‘major milestone’
By
Kimberly Bonvissuto
Sep 29, 2022
An investigational drug showing promise in reducing cognitive decline in early Alzheimer’s disease is being hailed as having potential to “change the course” of the disease.
Research focuses on diagnosing, lessening effects of Alzheimer’s disease
By
Kimberly Bonvissuto
Jun 28, 2022
More than 6 million Americans are living with Alzheimer’s disease, costing the nation $321 billion in 2022, according to the Alzheimer’s Association. A variety of studies and pilot programs are underway...
Smartphones: ‘digital dementia’ contributor or cognitive memory aid?
By
Kimberly Bonvissuto
May 04, 2022
Smartphones: friend or foe? It depends on whom you ask. Recent studies on smartphone use have found that mobile technology either can contribute to cognitive impairment or help improve cognition.